WAVE Life Sciences (WVE) Highlights Growth Strategy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
September 28, 2023 4:15 PM EDTPresented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Waves best-in-class GalNAc-siRNA capabilities and novel genetic insights from GSK
WVE-006 industrys first-ever RNA editing clinical candidate on track for dosing in RestorAATion clinical trial in 4Q 2023 and first human proof-of-mechanism data in 2024
Advancing multiple, wholly owned RNA editing targets using correction and upregulation approaches; leveraging proprietary deep-learning model to unlock additional targets across the edit-verse
Wave platform chemistry enabling extra-hepatic delivery in RNA... More
